Edwards Lifesciences’ (EW) Buy Rating Reaffirmed at BTIG Research

Edwards Lifesciences (NYSE:EW)‘s stock had its “buy” rating reissued by BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $103.00 price target on the medical research company’s stock. BTIG Research’s price objective indicates a potential upside of 33.77% from the company’s current price.

Other analysts also recently issued research reports about the stock. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Citigroup restated a “buy” rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Finally, Evercore reiterated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.86.

Edwards Lifesciences Stock Performance

Shares of EW opened at $77.00 on Wednesday. The company has a market cap of $44.68 billion, a price-to-earnings ratio of 33.19, a P/E/G ratio of 2.96 and a beta of 0.94. The business’s fifty day simple moving average is $83.83 and its two-hundred day simple moving average is $81.14. Edwards Lifesciences has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the previous year, the company earned $0.59 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 43,804 shares of company stock valued at $3,699,082. 0.34% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth approximately $25,000. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $28,000. True Wealth Design LLC boosted its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $28,000. Finally, NewSquare Capital LLC raised its holdings in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Institutional investors own 79.46% of the company’s stock.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Multiple sell‑side firms reiterated Buy ratings, highlighting sustained TAVR momentum, new structural‑heart catalysts, and attractive upside; these notes (with price targets above the current stock) support upside expectations for EW. Buy Rating on Edwards Lifesciences Driven by Strong Core TAVR Momentum, Conservative 2026 Guidance, and Attractive Risk‑Reward Profile
• Positive Sentiment: Bank of America reiterated a Buy and kept a $103 price target, citing margin upside and growth in LAAC and TAVR franchises. Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating
• Positive Sentiment: William Blair reiterated a Buy, pointing to TAVR tailwinds and new structural‑heart catalysts as key drivers for medium‑term upside. Edwards Lifesciences: Capitalizing on TAVR Tailwinds, New Structural Heart Catalysts, and Attractive Valuation Upside
• Positive Sentiment: Management raised its 2026 profit outlook above estimates and flagged robust demand for artificial heart valves — a near‑term positive signal that analysts pointed to in after‑hours trading. Edwards Lifesciences forecasts 2026 profit above estimates on heart devices strength
• Neutral Sentiment: Top‑line trends remain strong: Q4 sales grew ~13.3% y/y and TAVR sales increased about 12%, supporting the company’s long‑term structural thesis even as margins compress. Edwards Lifesciences Reports Fourth Quarter Results
• Neutral Sentiment: Full earnings call transcript and metric breakdowns are available for investors who want detail on product line performance and management’s commentary. Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings showed near‑term profitability pressure: adjusted EPS missed consensus (reported adjusted EPS ~$0.58 vs. ~$0.62 expected) and GAAP/operating profit contracted sharply year‑over‑year, which is weighing on sentiment despite revenue growth. Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Quarterly results and third‑party reports highlighted a sharp drop in net income and operating cash flow alongside notable insider selling activity — factors that can pressure near‑term valuation despite buy ratings. Edwards Lifesciences (EW) Stock Falls on Q4 2025 Earnings

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.